Private Health Forum 2023
The future of private healthcare will also be discussed at the Portfolio Private Health conference. Registration here!
Information and application
The recommendation is based on data showing that Enhertu reduced tumor size by 49% and the median duration of response to treatment by 16.8 months in patients previously treated for lung cancer.
The drug is already approved in the European Union for the treatment of patients with an advanced form of breast cancer. The recommendations made by the human medicine committee must be officially approved by the European Commission.
Cover image source: Getty Images
Leave a Comment